Major Ozonated Autoheamotherapy Alleviates Skeletal Muscle Ischemia/Reperfusion Injury by Regulating Nrf2/ HO ‐1 Pathway
The Kaohsiung Journal of Medical Sciences · 2025-08 · 41 (8)
DOI: 10.1002/kjm2.70039 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Kaohsiung Journal of Medical Sciences, online erschienen am 23.05.2025. Verfasst von Hui-Zhuang Guo und 2 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital of Jinan University, Guangzhou, China. Hauptthemen laut MEDLINE: NF-E2-Related Factor 2, Reperfusion Injury, Muscle, Skeletal, Ozone. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guangzhou Panyu District Science and Technology and Information Bureau Fund Project.
Abstract (Originalsprache)
Skeletal muscle ischaemia/reperfusion (I/R) injury remains a clinically significant condition characterized by muscular dystrophy. Although ozone therapy has shown protective potential against I/R injury in animal models of various organs including skeletal muscle, its precise mechanistic underpinnings require further elucidation. This investigation evaluates the therapeutic potential of major ozonated autohemotherapy (MOAH) for skeletal muscle I/R injury management. Utilizing a rat femoral artery ligation/release model, we demonstrated that MOAH pretreatment substantially alleviated histopathological damage through hematoxylin–eosin/Masson staining analyzes, diminished skeletal muscle apoptosis via terminal deoxynucleotidyl transferase dUTP nick‐end labeling and Western blot, and reduced tissue edema as quantified by wet weight ratios. Serum biomarker assessments confirmed decreased creatine kinase and lactate dehydrogenase levels with MOAH administration. In oxygen–glucose deprivation/reoxygenation (OGD/R)‐treated L6 myoblast models, ozone pretreatment enhanced cellular proliferation capacity while attenuating apoptosis and mitochondrial dysfunction. Subsequent analyzes revealed ozone's regulatory effects on oxidative stress markers (MDA content, SOD and CAT activity) and inflammatory factors (TNF‐α and IL‐1β) across both in vivo and in vitro models. Mechanistic evaluations through Western blot and reverse transcription quantitative real‐time polymerase chain reaction techniques identified MOAH‐induced activation of the Nrf2/HO‐1 signaling pathway, with observed abolition of protective efficacy under Nrf2 knockdown conditions. These results collectively establish that MOAH mitigates skeletal muscle I/R injury through Nrf2/HO‐1 pathway modulation, providing substantive mechanistic justification for its clinical implementation in I/R injury therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Affiliated Hospital of Jinan University, Guangzhou, China.
- Department of Radiology, The Affiliated Panyu Central Hospital, Guangzhou Medical University, Guangzhou, China.
- Department of Cardiovascular, The Affiliated Panyu Central Hospital, Guangzhou Medical University, Guangzhou, China.
- Panyu Health Management Center (Panyu Rehabilitation Hospital), Guangzhou, China.
ORCID-Profile: Han-Wei Chen
Förderung
- Guangzhou Panyu District Science and Technology and Information Bureau Fund Project
Zitieren
APA
Guo, H. Z., Yu, S. L., & Chen, H. W. (2025). Major Ozonated Autoheamotherapy Alleviates Skeletal Muscle Ischemia/Reperfusion Injury by Regulating Nrf2/ HO ‐1 Pathway. The Kaohsiung Journal of Medical Sciences, 41(8). https://doi.org/10.1002/kjm2.70039
Vancouver
Guo HZ, Yu SL, Chen HW. Major Ozonated Autoheamotherapy Alleviates Skeletal Muscle Ischemia/Reperfusion Injury by Regulating Nrf2/ HO ‐1 Pathway. The Kaohsiung Journal of Medical Sciences. 2025;41(8). doi:10.1002/kjm2.70039
BibTeX
@article{Guo2025,
author = {Guo, Hui-Zhuang and Yu, Sheng-Long and Chen, Han-Wei},
title = {Major Ozonated Autoheamotherapy Alleviates Skeletal Muscle Ischemia/Reperfusion Injury by Regulating Nrf2/ HO ‐1 Pathway},
journal = {The Kaohsiung Journal of Medical Sciences},
year = {2025},
volume = {41},
number = {8},
doi = {10.1002/kjm2.70039}
}
EUVIMED